Latest filing intelligence
REGENERON PHARMACEUTICALS, INC. (REGN)
Read the latest REGN filing as a structured brief: high-signal changes, financial snapshot, and direct links back to the official SEC source.
AI filing summary
REGENERON PHARMACEUTICALS, INC. latest filing summary
The filing reads constructive based on revenue and statement momentum.
The latest 10-K for REGN shows revenue was $14.3B and net income was $4.5B.
Key changes
What stands out in the latest report
- Revenue moved to $14.3B from $14.2B (+1.0% vs prior).
- Net income moved to $4.5B from $4.4B (+2.1% vs prior).
- Diluted EPS moved to $41.48 from $38.34 (+8.2% vs prior).
Current read
Positive read
Financial snapshot
Latest reported figures
Trend section
Recent revenue trend
Trend section
Recent EPS trend
Related links
Move through the research workflow
Related companies